ADHD Drugs May Get Black Box

 

A sharply divided panel of experts recommended that medications for attention deficit hyperactivity disorder carry the Food and Drug Administration's strictest warning about potential risks of heart damage and sudden death.

By a vote of 8 to 7, with one abstention, an advisory committee to the FDA said these drugs, including Novartis' (NVS) Ritalin and Shire Pharmaceuticals Group's (SHPGY) Adderall contain so-called black box warnings to alert patients and physicians to the possible problems.

The FDA isn't bound by its advisory panels' recommendations. The vote came during a meeting when medical experts were being asked to determine "research approaches" that could be used to study whether ADHD drugs increase the risk of heart problems, according to an FDA description of the gathering.

Although the FDA "has received case reports" of sudden death and heart damage, "these reports by themselves do not establish a causal relationship" between ADHD drugs and cardiac problems, said Gerald J. Dal Pan, director of the FDA's office of drug safety, in a written introduction to the advisory panel meeting.

However, panel members decided to act more emphatically, recommending that the black box warning be instituted. If subsequent tests prove there's no link between the drugs and heart disease, the black box warning could be removed, said one panel member according to Bloomberg News.

The FDA identified 11 brand-name ADHD drugs and some generics. Some brand-name drugs are closely related -- such as Shire's Adderall and Adderall XR -- and most are stimulants. The nonstimulant is Strattera from Eli Lilly (LLY). Other prominent brand names include Concerta from Johnson & Johnson (JNJ) and Focalin from Novartis.

The label for each ADHD drug has an assortment of warnings. For example, Strattera has a black box warning that refers to reports of suicidal thinking among children and adolescents. Labels for Adderall and Adderall XR warn about abusing amphetamines, which could lead to sudden death and heart damage.

TheStreet Premium Services    For Personal Service: 877-471-2967

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
New: ETF Profits
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Doug Kass
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,759.53 1,337.95 2,898.07 19.91
Oil *
116.87
DOWN
130.93
DOWN
14.00
DOWN
29.16
DOWN
0.56
10 Yr
1.99%
SPDR Gold
166.54
-1.02%
-1.04%
-1.00%
-2.74%
Data delayed 20 minutes

Top Stories and Tools

Brokerage Partners

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet